Ernexa Therapeutics Inc. (ERNA) Long-Term Investments (2021 - 2023)
Ernexa Therapeutics' (ERNA) quarterly Long-Term Investments came in at $8000.0 in Q1 2023, down 97.92% YoY from $385000.0 in Q1 2022, and down 86.44% on a QoQ basis from $59000.0 in Q4 2022.
Ernexa Therapeutics Inc. (ERNA) Long-Term Investments (2021 - 2023) Analysis & Trends
Ernexa Therapeutics (ERNA) has 3 years of Long-Term Investments data on file, last reported at $8000.0 in Q1 2023.
- Quarterly Long-Term Investments fell 97.92% year-over-year to $8000.0 in Q1 2023, while the trailing twelve-month figure through Mar 2023 was $8000.0 (down 97.92% YoY) and the FY2022 annual result came in at $59000.0, down 94.1% from the prior year.
- Long-Term Investments eased to $8000.0 in Q1 2023, from $59000.0 in the prior quarter.
- In the past five years, Long-Term Investments ranged from a high of $1.0 million in Q3 2021 to a low of $8000.0 in Q1 2023.
- A 3-year average of $372714.3 and a median of $89000.0 in 2022 frame the typical range for Long-Term Investments.
- Annual changes were most pronounced in 2022 — Long-Term Investments sank 93.2% — and 2023, when it tumbled 97.92%.
- Tracing ERNA's Long-Term Investments over 3 years: stood at $1.0 million in 2021, then plunged by 94.1% to $59000.0 in 2022, then slumped by 86.44% to $8000.0 in 2023.
- The last three Long-Term Investments figures came in at $8000.0 (Q1 2023), $59000.0 (Q4 2022), and $68000.0 (Q3 2022), per Business Quant data.
Powered by 
Peer Comparison
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2023 | 8,000.00 |
| Dec 31, 2022 | 59,000.00 |
| Sep 30, 2022 | 68,000.00 |
| Jun 30, 2022 | 89,000.00 |
| Mar 31, 2022 | 385,000.00 |
| Dec 31, 2021 | 1.00 Mn |
| Sep 30, 2021 | 1.00 Mn |